Table II.
Correlation of Aldo-ketoreductase family 1 member B10 expression with clinic opathological parameters in gastric cancer patient with neoadjuvant chemotherapy.
| AKR1B10 expression | |||
|---|---|---|---|
| Clinical factors | Positive (%) | Negative (%) | P-value |
| Age, years | 0.565 | ||
| <58 | 15 (57.7) | 11 (42.3) | |
| ≥58 | 16 (59.3) | 11 (40.7) | |
| Sex | 0.108 | ||
| Male | 21 (52.5) | 19 (47.5) | |
| Female | 10 (76.9) | 3 (23.1) | |
| Tumor size, cm | 0.211 | ||
| <5 | 18 (52.9) | 16 (47.1) | |
| ≥5 | 13 (68.4) | 6 (31.6) | |
| Tumor location | 0.236 | ||
| Cardia, fundus, body | 14 (51.9) | 13 (48.1) | |
| Antral | 17 (65.4) | 9 (34.6) | |
| Tumor staging | 0.171 | ||
| I–II | 13 (50.0) | 13 (50.0) | |
| III–IV | 18 (66.7) | 9 (33.3) | |
| Tumor depth | 0.259 | ||
| T1-T2 | 5 (45.5) | 6 (54.5) | |
| T3-T4 | 26 (61.9) | 16 (38.1) | |
| Lymph node metastasis | 0.020a | ||
| Yes | 25 (69.4) | 11 (30.6) | |
| No | 6 (35.3) | 11 (64.7) | |
| Histological differentiation | 0.399 | ||
| Differentiated | 15 (62.5) | 9 (37.5) | |
| Undifferentiated | 16 (55.2) | 13 (44.8) | |
| Tumor regression grade | 0.033a | ||
| 0–2 | 23 (69.7) | 10 (30.3) | |
| 3–4 | 8 (40.0) | 12 (60.0) | |
| Chemotherapy regimen | 0.583 | ||
| FOLFOX | 13 (59.1) | 9 (40.9) | |
| EOX | 8 (50.0) | 8 (50.0) | |
| Others (SOX, ECX, EOS, S1) | 8 (61.5) | 5 (38.5) | |
| Chemoradiotherapy | 2 (100.0) | 0 (0.0) | |
| Chemotherapy cycle | 0.768 | ||
| 2 | 4 (50.0) | 4 (50.0) | |
| 3 | 11 (64.7) | 6 (35.3) | |
| ≥4 | 16 (57.1) | 12 (42.9) | |
a
P-value <0.05. ECX, epirubicin + cisplatin + capecitabine; EOS, epirubicin + oxaplatin + tegafur; EOX, epirubicin + oxaplatin + capecitabine; FOLFOX, oxaplatin + leucovorin + 5-FU; S1, tegafur; SOX, oxaplatin + tegafur.